Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: A meta-analysis

Reproductive Biology and Endocrinology

Volumn 14, Issue 1, 2016, Pages

  Yang, Rui ^a   Yang, Shuo ^a   Li, Rong ^a   Liu, Ping ^a   Qiao, Jie ^a   Zhang, Yanwu ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INSTITUTE OF MEDICAL INFORMATION   (China)

Author keywords

Hyperandrogenism; Meta analysis; Metabolic disorder; PCOS

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DISEASE ASSESSMENT; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE INDEX; HUMAN; HYPERANDROGENISM; INCIDENCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PUBLISHING; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; CHINA; CLINICAL TRIAL (TOPIC); FEMALE; META ANALYSIS; METABOLISM; PHYSIOLOGY; PROCEDURES;

CHINA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME; OBSERVATIONAL STUDIES AS TOPIC; POLYCYSTIC OVARY SYNDROME;

EID: 84992445074     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/s12958-016-0203-8     Document Type: Review

References (37)

1. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med. 1995;98(1A):33S-9.
2. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract. 2007;77 Suppl 1:S243-6.
3. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
4. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. PLoS Negl Trop Dis. 2013;7(5):e2195.
5. Rostom A, Dubé C, Cranney A, Saloojee N, Sy R, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, McNeil J, Moher D, Mack D, Patel D. Celiac disease. Rockville: Agency for Healthcare Research and Quality (US); 2004.
6. Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, Azizi F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. Clin Endocrinol (Oxf). 2014;81(1):93-9.
7. Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ, Park CW, Choi DS, Kang BM, Lee BS, Kim T, Park HY. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PLoS One. 2014;9(6):e99252.
8. Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One. 2014;9(10):e108263.
9. Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, Kaldrymides P, Panidis D, Diamanti-Kandarakis E. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine. 2014;47(2):631-8.
10. Sung YA, Oh JY, Chung H, Lee H. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertil Steril. 2014;101(3):840-5.
11. Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014;12:89.
12. Ates S, Sevket O, Sudolmus S, Dane B, Ozkal F, Uysal O, Dansuk R. Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics. Gynecol Endocrinol. 2013;29(10):931-5.
13. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, Zambotti F, Dall'Alda M, Caruso B, Zanolin ME, Bonora E, Moghetti P. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98(6):2581-8.
14. Zhu JP, Teng YC, Zhou J, Lu W, Tao MF, Jia WP. Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring. Acta Obstet Gynecol Scand. 2013;92(2):165-71.
15. Gluszak O, Stopinska-Gluszak U, Glinicki P, Kapuscinska R, Snochowska H, Zgliczynski W, Debski R. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:569862.
16. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709-16.
17. Li Y, Ma Y, Chen X, Wang W, Li Y, Zhang Q, Yang D. Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. J Assist Reprod Genet. 2012;29(10):1147-51.
18. Ozkaya E, Cakir E, Cinar M, Kara F, Baser E, Cakir C, Kucukozkan T. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS? Gynecol Endocrinol. 2012;28(6):468-71.
19. Cupisti S, Haeberle L, Schell C, Richter H, Schulze C, Hildebrandt T, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. Exp Clin Endocrinol Diabetes. 2011;119(8):502-8.
20. Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011;16(6):763-9.
21. Melo AS, Vieira CS, Romano LG, Ferriani RA, Navarro PA. The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci. 2011;18(12):1230-6.
22. Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, Yapa C, Seneviratne Rde A, Balen AH. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod. 2011;26(1):202-13.
23. Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res. 2011;37(8):1020-6.
24. Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol. 2010;26(10):736-42.
25. Guo M, Chen ZJ, Macklon NS, Shi YH, Westerveld HE, Eijkemans MJ, Fauser BC, Goverde AJ. Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. Reprod Biomed Online. 2010;21(4):572-80.
26. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009;24(3):710-7.
27. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66(4):513-7.
28. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88(5):1389-95.
29. Chen H, Yang ZF, Zhan WW, La DD, Chen C. Ultrasonographic features of polycystic ovary syndrome and their correlation with endocrinology index. J Diagn Concepts Pract. 2014;13(2):171-5.
30. Li YC. Relationship of lipid metabolism disturbance with body weight, insulin resistance and androgen level in patients with polycystic ovary syndrome. Matern Child Health Care China. 2014;29:354-6.
31. Ha LX, Shi YH, Zhao JL, Chen ZJ. Lipid metabolism characteristics in polycystic ovary syndrome patientswith different androgen levelsin Ningxia. J Shandong University (Med Sci). 2013;51:88-91.
32. Tao T, Liu W, Zhao AM, Li SX, Zheng J, Wang LH, Zhou JW, Huang R, Zhang P. Characteristics and risk of metabolic syndrome in patients with different phenotypes of polycystic ovary syndrome. Chin J Endocrinol Metab. 2013;29:200-5.
33. Li J, Xu C, Zhang HJ, Hong J, Ning G, Li XY. Correlation of obesity with hyperandrogenism and insulin resistance in patients with polycystic ovary syndrome. Chin J Endocrinol Metab. 2011;27:733-5.
34. Liu L, Shao JB, Zhang HP, Shen XL. Metabolism characteristics in patients with different phenotypes of polycystic ovary syndrome. Clin Educ Gen Pract. 2011;9:505-7.
35. Qu ZY, Shi YH, Chen ZJ. Relationship between hyperandrogenism and non-alcoholic fatty liver disease of polycystic ovary syndrome. Reprod Contracept. 2011;31:14-7.
36. Xu LS, Zhang YF, Zhang HY, Xue FX, Han YK. Glucose metabolism characteristics in patients with different phenotypes of polycystic ovary syndrome. Prog Obstet Gynecol. 2010;19:333-5.
37. Zhang L, Zhang Y. Correlation of androgen level with insulin resistance in patients with polycystic ovary syndrome. Exp Lab Med. 2010;28:239-40.